Business
Kelyniam Global, Inc., Announces Strategic Licensing Agreement with Fin-ceramica faenza spa to Market Hydroxyapatite Cranial Implant in the U.S.
Kelyniam Global, Inc., Announces Strategic Licensing Agreement with Fin-ceramica faenza spa to Market Hydroxyapatite Cranial Implant in the U.S..
About this update from Kelyniam Global, Inc.
[{"type":"text","content":"\n\n\n\nKelyniam Global, Inc., Announces Strategic Licensing Agreement with Fin-ceramica faenza spa to Market Hydroxyapatite Cranial Implant in the U.S.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nKelyniam Global, Inc., Announces Strategic Licensing Agreement with Fin-ceramica faenza spa to Market Hydroxyapatite Cranial Implant in the U.S.\nEuropean market leading implant now available in the U.S.\nPR Newswire\nCOLLINSVILLE, Conn., Dec. 22, 2021\n\n\n\nCOLLINSVILLE, Conn., Dec. 22, 2021 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial PEEK implants today announced that it has entered into a strategic licensing agreement with Fin-ceramica faenza spa to market the company's hydroxyapatite patient specific implant.  This bio-mimetic ceramic biomaterial is based on macro and micro porous Hydroxyapatite (HA), a major (70%) component of human bone. The specific bio-mimetic chemical composition combined with an elevated interconnected porosity play a role in the perimetral osteointegration process.\nThe innovative CustomizedBone Service™ implant is indicated for use in adult and pediatric patients (for children 7 years of age and above). The highly bio-compatible material, shows a reduced post-op infection incidence compared to titanium-based implants.\n\"We are extremely excited to partner with a technology leading company like Fin-ceramica,\" said Ross Bjella, Kelyniam's CEO. \"Our companies share a mutual passion of working closely with neurosurgeons to design and build complex implants for cranial and maxillo-facial applications. The CustomizedBoneä implant will give our customers another terrific option to fill a specific patient need.\" \nKelyniam will distribute the implant through its active salesforce of more than 50 representatives starting in January.  Representatives will carry both PEEK (polyether ether ketone) and hydroxyapatite products.  The CustomizedBoneä implant was previously marketed in the U.S. by Integra Lifesciences. \nLaura Reed, Kelyniam's National Sales D...